We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Test Enables Early Diagnosis of Chlamydia

By HospiMedica staff writers
Posted on 17 May 2006
A highly sensitive, qualitative 90-minute test has been developed for detection of Chlamydia trachomatis (C trachomatis), even in the early stages of infection. More...


Chlamydia is one of the most common sexually transmitted diseases (STDs). In addition to urogenital disease, C trachomatis causes trachoma, a chronic, recurrent infection of the conjunctiva and cornea, especially widespread in the tropics. According to the World Health Organization (WHO, Geneva, Switzerland), 500 million people worldwide are in danger of infection, over 140 million are already infected, and more than six million have been blinded due to chlamydia infection, mostly in developing countries.

The C trachomatis bacterium contains five to 10 copies of a conserved 7.5 kb cryptic plasmid. Using this plasmid as a target enables highly sensitive detection of C trachomatis. However, since plasmid-free C trachomatis bacteria have also been previously detected, conventional tests for C trachomatis that are based solely on detection of the chlamydial cryptic plasmid are not always reliable.

The CE-marked Artus C trachomatis plus polymerase chain reaction (PCR) kit produced by Qiagen (Hamburg, Germany) detects a region of the ompA gene, which encodes the major outer membrane protein (MOMP), in addition to sequences on the cryptic plasmid.

This highly sensitive, qualitative detection system enables early detection of chlamydia during routine testing, enabling diagnosis of chlamydia infection in the early stages of infection, even with plasmid-free variants of C trachomatis. This is a significant step forward in chlamydia detection, said Dr. Ulrich Spengler, managing director of Qiagen Hamburg GmbH, because serious consequences, such as sterility and blindness, can be prevented by early treatment. In contrast to traditional methods, the Artus C trachomatis plus PCR kit is the only system worldwide that detects both the chlamydial cryptic plasmid and the ompA gene in parallel.

Artus C trachomatis plus PCR kits are ready-to-use reagent systems for detection of C trachomatis DNA by real-time PCR. An internal control, supplied with the kits, serves as a control for DNA purification and to detect false negatives due to possible PCR inhibition. Excellent sensitivity and specificity have been demonstrated during validation of the kits using swab, urine, and sperm samples.



Related Links:
Qiagen

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Desk Aneroid Sphyg
Diagnostix 750D+
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.